Epic Sciences
  • Technology
  • Products
    • DefineMBC
    • AR-V7
  • Biopharma
    Solutions
  • Publications &
    Resources
    • PUBLICATIONSNEW
    • SCIENTIFIC POSTERSNEW
    • PACKAGE INSERTSNEW
    • LIBRARYNEW
    • PODCASTS & WEBINARSNEW
  • News &
    Events
    • PRESS RELEASESNEW
    • NEWSNEW
    • EVENTSNEW
  • Company
    • EPIC STORY
    • CAREERS
    • LEADERSHIP
  • Contact
  • Sign Up
  • LATEST NEWS Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel Read More

CE Mark Blood Collection Kit Package Insert (Kit FM-000107)

English CE Mark Blood Collection Kit Package Insert
French CE Mark Blood Collection Kit Package Insert
German CE Mark Blood Collection Kit Package Insert
Spanish CE Mark Blood Collection Kit Package Insert
Czech CE Mark Blood Collection Kit Package Insert
Italian CE Mark Blood Collection Kit Package Insert
Polish CE Mark Blood Collection Kit Package Insert
Dutch CE Mark Blood Collection Kit Package Insert
Danish CE Mark Blood Collection Kit Package Insert
Slovakian CE Mark Blood Collection Kit Package Insert
Finnish CE Mark Blood Collection Kit Package Insert
Swedish CE Mark Blood Collection Kit Package Insert
ALL INSERTS

Menu

  • AR-V7 Test
  • Biopharma Solutions
  • Publications
  • News Center
  • Company
  • Careers
  • Contact Us
  • Privacy Policy

9381 Judicial Drive, Suite 200
San Diego, CA 92121

Main Number: 858-356-6610
Customer Success: 800-941-0522

General Information:[email protected]

Investor Relations:[email protected]

Media Inquiries:[email protected]

HR Inquiries:[email protected]

Customer Success:[email protected]

©2020 Epic Sciences
v.B – LBL 00074 – 2020
‘No Cell Left Behind’ and ‘The Power of Clarity’ are registered trademarks of Epic Sciences in the United States.

Epic Sciences is licensed under the federal Clinical Laboratory Improvements Act of 1988 (CLIA), accredited by the College of American Pathologists (CAP), and is authorized to provide diagnostic services in all states including those states which require state-specific approvals including California, New York, Maryland, Pennsylvania, and Rhode Island.